Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial 
MENLO PARK, Calif., Nov. 07, 2017 -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the following investor conferences:
- Stifel 2017 Healthcare Conference in New York at 4:15 p.m. ET on Tuesday, November 14, 2017.
- Piper Jaffray 29th Annual Healthcare Conference in New York at 3:30 p.m. ET on Tuesday, November 28, 2017.
A live audio webcast of each presentation will be available through the Investors section of Geron’s website (www.geron.com) under Events. Following the live presentations, the webcasts will be archived and available for replay for a period of 30 days.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT:
Anna Krassowska, Ph.D.
Investor and Media Relations
650-473-7765
[email protected]
[email protected]
